Piper Brian 4

What Happened

• Brian Piper, Chief Financial Officer of Sana Biotechnology (SANA), was granted two derivative awards on February 17, 2026 totaling 1,100,000 units: 200,000 restricted stock units (RSUs) and 900,000 additional award units. Both awards show an acquisition price of $0.00 (i.e., no cash paid by the insider).
• Per the filing footnotes, each RSU is a contingent right to receive one share of common stock on vesting. The 200k RSUs vest in four equal annual installments on Feb 17 of 2027, 2028, 2029 and 2030. The 900k award vests 25% on Feb 17, 2027 and then in 36 equal monthly installments thereafter.

Key Details

• Transaction date: 2026-02-17; Form 4 filed: 2026-02-18 (timely filing).
• Grants: 200,000 RSUs @ $0.00; 900,000 derivative award units @ $0.00 (total = 1,100,000 units).
• Vesting: 200k RSUs — four equal annual installments (Feb 17, 2027–2030). 900k award — 25% on Feb 17, 2027 then 36 monthly installments (per footnote).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Transaction code: A = Award/Grant. No indication of 10b5-1 plan, tax withholding, cashless sale, or gift in the provided notes.

Context

• These are compensation/retention awards (not open-market purchases or sales). RSUs are rights to receive shares upon vesting; the 900k award follows a common executive vesting schedule (one-year cliff then monthly vesting). Such grants are typical for newly hired or retained executives and do not by themselves indicate current buying or selling sentiment.